These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 2757884)

  • 1. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.
    Drøhse A; Bathum L; Brøsen K; Gram LF
    Br J Clin Pharmacol; 1989 May; 27(5):620-5. PubMed ID: 2757884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.
    Sindrup SH; Brøsen K; Hansen MG; Aaes-Jørgensen T; Overø KF; Gram LF
    Ther Drug Monit; 1993 Feb; 15(1):11-7. PubMed ID: 8451774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians.
    Inaba T; Jurima M; Nakano M; Kalow W
    Clin Pharmacol Ther; 1984 Nov; 36(5):670-6. PubMed ID: 6488688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.
    Brøsen K; Skjelbo E; Flachs H
    Br J Clin Pharmacol; 1993 Aug; 36(2):105-8. PubMed ID: 8398577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.
    Madsen H; Nielsen KK; Brøsen K
    Br J Clin Pharmacol; 1995 Apr; 39(4):433-9. PubMed ID: 7640151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sparteine and mephenytoin oxidation: genetic polymorphisms in east and west Greenland.
    Clasen K; Madsen L; Brøsen K; Albøge K; Misfeldt S; Gram LF
    Clin Pharmacol Ther; 1991 Jun; 49(6):624-31. PubMed ID: 2060251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sparteine oxidation polymorphism in Greenlanders living in Denmark.
    Brøsen K
    Br J Clin Pharmacol; 1986 Oct; 22(4):415-9. PubMed ID: 3768256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.
    Nielsen KK; Brøsen K; Hansen MG; Gram LF
    Clin Pharmacol Ther; 1994 May; 55(5):518-27. PubMed ID: 8181196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population.
    Basci NE; Brosen K; Bozkurt A; Isimer A; Sayal A; Kayaalp SO
    Br J Clin Pharmacol; 1994 Nov; 38(5):463-5. PubMed ID: 7893589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sparteine oxidation polymorphism in Denmark.
    Brøsen K; Otton SV; Gram LF
    Acta Pharmacol Toxicol (Copenh); 1985 Nov; 57(5):357-60. PubMed ID: 4090995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design.
    Schellens JH; van der Wart JH; Brugman M; Breimer DD
    J Pharmacol Exp Ther; 1989 May; 249(2):638-45. PubMed ID: 2724144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine.
    Skjelbo E; Brøsen K; Hallas J; Gram LF
    Clin Pharmacol Ther; 1991 Jan; 49(1):18-23. PubMed ID: 1988236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sparteine oxidation polymorphism: a family study.
    Brøsen K; Otton SV; Gram LF
    Br J Clin Pharmacol; 1986 Jun; 21(6):661-7. PubMed ID: 3741716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
    Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
    Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese.
    Horai Y; Nakano M; Ishizaki T; Ishikawa K; Zhou HH; Zhou BI; Liao CL; Zhang LM
    Clin Pharmacol Ther; 1989 Aug; 46(2):198-207. PubMed ID: 2758729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sparteine oxidation by the human liver: absence of inhibition by mephenytoin.
    Jurima M; Inaba T; Kalow W
    Clin Pharmacol Ther; 1984 Mar; 35(3):426-8. PubMed ID: 6697650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study.
    Skjelbo E; Gram LF; Brøsen K
    Br J Clin Pharmacol; 1993 Mar; 35(3):331-4. PubMed ID: 8471415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with a co-regulated substrate, mephobarbital.
    Jacqz E; Hall SD; Branch RA; Wilkinson GR
    Clin Pharmacol Ther; 1986 Jun; 39(6):646-53. PubMed ID: 3709029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphic drug oxidation in humans.
    Eichelbaum M
    Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans.
    Schellens JH; Ghabrial H; van der Wart HH; Bakker EN; Wilkinson GR; Breimer DD
    Clin Pharmacol Ther; 1991 Nov; 50(5 Pt 1):520-8. PubMed ID: 1934865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.